EP1918303A3 - method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment - Google Patents

method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment Download PDF

Info

Publication number
EP1918303A3
EP1918303A3 EP07019042A EP07019042A EP1918303A3 EP 1918303 A3 EP1918303 A3 EP 1918303A3 EP 07019042 A EP07019042 A EP 07019042A EP 07019042 A EP07019042 A EP 07019042A EP 1918303 A3 EP1918303 A3 EP 1918303A3
Authority
EP
European Patent Office
Prior art keywords
egp
stabilization
scfv fragment
chimeric immunoglobulins
immunoglobulin fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07019042A
Other languages
German (de)
French (fr)
Other versions
EP1918303A2 (en
Inventor
Andreas Plückthun
Annemarie Honneger
Jörg WILLUDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Zuerich
Original Assignee
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Zuerich filed Critical Universitaet Zuerich
Priority to EP07019042A priority Critical patent/EP1918303A3/en
Publication of EP1918303A2 publication Critical patent/EP1918303A2/en
Publication of EP1918303A3 publication Critical patent/EP1918303A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A61K47/6823—Double chain ricin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
EP07019042A 1999-04-09 2000-04-10 method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment Withdrawn EP1918303A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07019042A EP1918303A3 (en) 1999-04-09 2000-04-10 method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99107030 1999-04-09
EP00926853A EP1171468B1 (en) 1999-04-09 2000-04-10 Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
EP07019042A EP1918303A3 (en) 1999-04-09 2000-04-10 method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP00926853A Division EP1171468B1 (en) 1999-04-09 2000-04-10 Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment

Publications (2)

Publication Number Publication Date
EP1918303A2 EP1918303A2 (en) 2008-05-07
EP1918303A3 true EP1918303A3 (en) 2008-05-14

Family

ID=8237927

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00926853A Expired - Lifetime EP1171468B1 (en) 1999-04-09 2000-04-10 Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
EP07019042A Withdrawn EP1918303A3 (en) 1999-04-09 2000-04-10 method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00926853A Expired - Lifetime EP1171468B1 (en) 1999-04-09 2000-04-10 Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment

Country Status (10)

Country Link
US (4) US7033798B2 (en)
EP (2) EP1171468B1 (en)
JP (1) JP4540856B2 (en)
AT (1) ATE399796T1 (en)
CA (1) CA2369622C (en)
DE (1) DE60039354D1 (en)
DK (1) DK1171468T3 (en)
ES (1) ES2308981T3 (en)
PT (1) PT1171468E (en)
WO (1) WO2000061635A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540856B2 (en) * 1999-04-09 2010-09-08 ウニヴェルジテート・チューリッヒ Novel method for stabilizing chimeric immunoglobulins or immunoglobulin fragments and stabilized anti-EGP-2 scFv fragments
EP1551453A4 (en) 2002-06-17 2007-04-25 Us Gov Health & Human Serv Specificity grafting of a murine antibody onto a human framework
ES2639301T3 (en) * 2003-04-30 2017-10-26 Universität Zürich Cancer treatment procedures using an immunotoxin
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
EP2322622A3 (en) 2005-03-25 2012-03-07 National Research Council of Canada Method for isolation of soluble polypeptides
ES2363891T3 (en) * 2006-03-20 2011-08-18 The Regents Of The University Of California ANTIBODIES AGAINST THE ANTIGEN OF TRONCAL CELLS OF THE PROSTATE (PSCA) GENETICALLY MODIFIED FOR ADDRESSING TO CANCER.
MX2008012146A (en) 2006-03-28 2008-10-03 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof.
CN101842116A (en) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 Compositions that bind multiple epitopes of IGF-1R
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP3714906A1 (en) * 2007-10-03 2020-09-30 Cornell University Treatment of proliferative disorders using radiolabelled antibodies to psma
US8728479B2 (en) 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
SG11201602170XA (en) 2013-10-02 2016-04-28 Viventia Bio Inc Anti-epcam antibodies and methods of use
DK3189132T3 (en) 2014-09-04 2020-08-10 Stemcell Tech Inc Soluble antibody complexes for T cell or NK cell activation and expansion
CN107580501A (en) 2015-03-12 2018-01-12 维文蒂亚生物公司 For targetting the administration strategy of EPCAM positive carcinomas of urinary bladder
CA2979394A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
CN108779174B (en) * 2015-11-04 2022-11-29 希望之城公司 Chimeric antigen receptor targeting HER2
JP6644956B2 (en) * 2016-09-07 2020-02-12 サクシン ライフサイエンシス ピーヴィーティー エルティディーＳａｋｓｉｎ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｐｖｔ Ｌｔｄ Synthetic antibodies to VEGF and uses thereof
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
CN110194803B (en) * 2019-06-26 2021-01-05 上海科棋药业科技有限公司 EpCAM-targeted chimeric antigen receptor and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540856B2 (en) * 1999-04-09 2010-09-08 ウニヴェルジテート・チューリッヒ Novel method for stabilizing chimeric immunoglobulins or immunoglobulin fragments and stabilized anti-EGP-2 scFv fragments
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
ES2639301T3 (en) * 2003-04-30 2017-10-26 Universität Zürich Cancer treatment procedures using an immunotoxin

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
HONEGGER A ET AL: "The Influence of the Buried Glutamine or Glutamate Residue in Position 6 on the Structure of Immunoglobulin Variable Domains", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 309, no. 3, 8 June 2001 (2001-06-08), pages 687 - 699, XP004626895, ISSN: 0022-2836 *
HSU E ET AL: "Evolution of immunoglobulin genes: VH families in the amphibian Xenopus.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA OCT 1989, vol. 86, no. 20, October 1989 (1989-10-01), pages 8010 - 8014, XP002473847, ISSN: 0027-8424 *
JOHANSSON JEANNETTE ET AL: "Heavy chain V region diversity in the duck-billed platypus (Ornithorhynchus anatinus): long and highly variable complementarity-determining region 3 compensates for limited germline diversity.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAY 2002, vol. 168, no. 10, 15 May 2002 (2002-05-15), pages 5155 - 5162, XP002473846, ISSN: 0022-1767 *
JUNG S ET AL: "Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting.", PROTEIN ENGINEERING, vol. 10, no. 8, August 1997 (1997-08-01), pages 959 - 966, XP002085709 *
KEHOE J M ET AL: "Sequence relationships among the variable regions of immunoglobulin heavy chains from various mammalian species.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA AUG 1972, vol. 69, no. 8, August 1972 (1972-08-01), pages 2052 - 2055, XP002473848, ISSN: 0027-8424 *
KREBBER A ET AL: "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 201, no. 1, 14 February 1997 (1997-02-14), pages 35 - 55, XP002151868 *
LANGEDIJK A C ET AL: "THE NATURE OF ANTIBODY HEAVY CHAIN RESIDUE H6 STRONGLY INFLUENCES THE STABILITY OF A VH DOMAIN LACKING THE DISULFIDE BRIDGE", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 283, no. 1, 16 October 1997 (1997-10-16), pages 95 - 110, XP004457295, ISSN: 0022-2836 *
NGUYEN V K ET AL: "Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 5, May 2000 (2000-05-01), pages 921 - 930, XP002188947, ISSN: 0261-4189 *
PROBA K ET AL: "Antibody scFv fragments without disulfide bonds made by molecular evolution.", JOURNAL OF MOLECULAR BIOLOGY, vol. 275, no. 2, 16 January 1998 (1998-01-16), pages 245 - 253, XP000944603 *
SAUL F A ET AL: "STRUCTURAL PATTERNS AT RESIDUE POSITIONS 9, 18, 67 AND 82 IN THE VH FRAMEWORK REGIONS OF HUMAN AND MURINE IMMUNOGLOBULINS", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 230, no. 1, 5 March 1993 (1993-03-05), pages 15 - 20, XP000944600, ISSN: 0022-2836 *
SAUL F A: "Structural implications of VH sequence patterns.", RESEARCH IN IMMUNOLOGY JAN 1994, vol. 145, no. 1, January 1994 (1994-01-01), pages 61 - 66, XP002473845, ISSN: 0923-2494 *
WAIBEL R ET AL: "Stable one-step technetium -99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex [see comments].", NATURE BIOTECHNOLOGY, vol. 17, no. 9, September 1999 (1999-09-01), pages 897 - 901, XP002156715 *
WILLUDA J ET AL: "HIGH THERMAL STABILITY IS ESSENTIAL FOR TUMOR TARGETING OF ANTIBODY FRAGMETS: ENGINEERING OF A HUMANIZED ANTI-EPITHELIAL GLYCOPROTEIN-2 (EPITHELIAL CELL ADHESION MOLECULE) SINGLE-CHAIN FV FRAGMENT", CANCER RESEARCH,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD,US, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5758 - 5767, XP000941616, ISSN: 0008-5472 *
WILLUDA, J. (1) ET AL: "Rational engineering for high stability is required for tumor targeting o a high-affinity scFv fragment specific for the panepithelial glycoprotein EGP-2 (EP-CAM.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, P. 354, ABST. 2343,MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999, March 1999 (1999-03-01), XP000941670 *
ZAMORA P O ET AL: "IMIDAZOLES AS WELL AS THIOLATES IN PROTEINS BIND TECHNETIUM-99M", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 3, no. 6, 1992, pages 493 - 498, XP009064650, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
JP4540856B2 (en) 2010-09-08
WO2000061635A3 (en) 2001-05-10
ATE399796T1 (en) 2008-07-15
US20020146846A1 (en) 2002-10-10
DK1171468T3 (en) 2008-10-20
JP2002542773A (en) 2002-12-17
WO2000061635A2 (en) 2000-10-19
US20110136173A1 (en) 2011-06-09
US7341722B2 (en) 2008-03-11
US20080299124A1 (en) 2008-12-04
EP1171468A2 (en) 2002-01-16
EP1918303A2 (en) 2008-05-07
CA2369622A1 (en) 2000-10-19
US8137932B2 (en) 2012-03-20
DE60039354D1 (en) 2008-08-14
EP1171468B1 (en) 2008-07-02
US7033798B2 (en) 2006-04-25
US7858088B2 (en) 2010-12-28
US20060159683A1 (en) 2006-07-20
CA2369622C (en) 2011-06-14
PT1171468E (en) 2008-10-08
ES2308981T3 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
EP1918303A3 (en) method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
WO2001010381A3 (en) Methods for treating or preventing pain and anxiety
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
WO2001000245A3 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
IL189629A0 (en) Compositions containing human ctla-4 antibodies
HK1069586A1 (en) Anti-her2 antibody variants anti-her2
EP1277792A3 (en) Biodegradable plastic composition and method for control of biodegradation rate of biodegradable plastic
EP0696441A3 (en) Means for the stabilization of long bones, especially for the osteotomy
WO2001001970A3 (en) New uses potassium channel openers, such as the treatment of epilepsy
AU4399297A (en) Reconstituted human anti-hm1.24 antibody
HUP9903995A3 (en) Output choke for d.c. welder and method for controlling same
WO2003051886A8 (en) Pyrazolopyridazine derivatives
AU6263899A (en) Method for treating androgen-related conditions
HK1040625A1 (en) Method for improving the pharmacokinetics of tipranavir.
AUPR617901A0 (en) Method for treating multiple myeloma
AU2002213937A1 (en) Method for modifying the genome of corynebacteria
WO2003008451A3 (en) Modification of human variable domains
AUPM835394A0 (en) Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
AU2001285747A1 (en) Method for the treatment of tobacco
AU2825295A (en) Method for the treatment, prevention or minimization of hair loss
MA25586A1 (en) METHOD FOR THE CONTROL OF FRUIT FLIES.
AU4748893A (en) Reshaped monocolonal antibodies against an immunoglobulin isotype
ZA9810215B (en) 2-Aryl-3-Aroylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome.
WO2002083842A3 (en) Small molecule inhibitors of secretion of proteins encoded by are-mrnas
WO2001035087A3 (en) A gas sensor seal and method of producing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 20071024

AC Divisional application: reference to earlier application

Ref document number: 1171468

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1115889

Country of ref document: HK

17Q First examination report despatched

Effective date: 20081212

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090623

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1115889

Country of ref document: HK